BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34840089)

  • 21. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
    Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
    Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
    Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
    Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratifying MDS in the time of precision medicine.
    Cazzola M
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
    Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
    Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
    Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
    Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance.
    Shin DY; Park JK; Kim SM; Im K; Kim JA; Kim SY; Hwang SM; Yoon SS; Lee DS
    Leuk Lymphoma; 2019 Mar; 60(3):756-763. PubMed ID: 30301403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
    Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
    BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
    Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes].
    Nagata Y; Ogawa S
    Rinsho Ketsueki; 2017; 58(7):776-786. PubMed ID: 28781274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
    Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
    Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
    Vobugari N; Heuston C; Lai C
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.